Moshe Ornstein, MD

Articles

Optimizing Treatment in Advanced RCC

July 22nd 2024

Martin H. Voss, MD, provides valuable insights into determining the optimal duration of treatment with lenvatinib plus pembrolizumab in patients with advanced renal clear cell carcinoma, emphasizing the importance of close patient monitoring and the critical decision-making process involved in continuing or discontinuing treatment based on individual patient response, tolerability, and overall clinical status in real-world clinical practice settings.

AE Management for Combination Regimens in Advanced RCC

July 22nd 2024

The key opinion leaders engage in discussion on dose reduction and treatment duration rates in the context of the CLEAR study, which investigated lenvatinib plus pembrolizumab in advanced renal cell carcinoma (RCC), addressing important aspects such as optimal starting doses, the potential for reverting to higher doses, and the implications of these strategies on overall treatment efficacy and patient outcomes.

AE Management for Combination Regimens in Advanced RCC

July 22nd 2024

The key opinion leaders engage in discussion on dose reduction and treatment duration rates in the context of the CLEAR study, which investigated lenvatinib plus pembrolizumab in advanced renal cell carcinoma (RCC), addressing important aspects such as optimal starting doses, the potential for reverting to higher doses, and the implications of these strategies on overall treatment efficacy and patient outcomes.

Treatment Decision Making in first-line combinations for advanced RCC

July 16th 2024

The key opinion leaders explore the various first-line combination treatment options for advanced renal cell carcinoma, including immuno-oncology plus immuno-oncology (IO+IO) and immuno-oncology plus tyrosine kinase inhibitor (IO+TKI) approaches, while also considering the optimal sequencing of treatments to maximize patient benefit.

Use of Combination Regimens in Frontline RCC

July 8th 2024

Martin H. Voss, MD, presents data supporting the use of various combination regimens in the frontline treatment of renal cell carcinoma (RCC), focusing on the pivotal trials such as CheckMate 214, KEYNOTE 426, and the CLEAR trial, emphasizing their respective efficacy, safety, and overall impact on the current treatment landscape for RCC patients.

Case Presentation: 61-year-old male Renal Cell Carcinoma

July 8th 2024

Moshe Ornstein, MD, presents a detailed clinical case study of a 61-year-old male patient diagnosed with renal cell carcinoma.

STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

July 2nd 2024

Dr. Martin H. Voss provides an analysis of the recent data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, focusing on the phase 3 STELLAR trial, which evaluates the safety and efficacy of the combination therapy Zanzalintinib and nivolumab in patients with non-clear cell renal cell carcinoma.

Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

July 2nd 2024

Moshe Ornstein, MD, presents an overview of the current front-line treatment options for advanced non-clear cell renal cell carcinoma, focusing on the PAPMET regimen and the promising results from the Phase 2 study investigating the combination of nivolumab and cabozantinib.

Extended Follow Up of KEYNOTE-B61

June 24th 2024

Martin H. Voss, MD, provides an update on the extended follow-up data from the phase 2 KEYNOTE-B61 study, which investigates the efficacy and safety of combination therapy consisting of pembrolizumab and lenvatinib as a first-line treatment option for patients with advanced non-clear cell renal cell carcinoma.

Evolving Treatment Standards in Non-Clear Cell RCC

June 24th 2024

Martin H. Voss, MD, and Moshe Ornstein, MD, engage in a professional discourse concerning the current treatment standards and the evolving therapeutic landscape for non-clear cell renal cell carcinoma (RCC).

Exciting Investigational Therapies in Advanced RCC

January 23rd 2023

The oncologists close their discussion with a look at some currently ongoing clinical trials in advanced renal cell carcinoma treatment.

Emerging Data in Non-Clear Cell RCC Treatment

January 16th 2023

Hans Hammers, MD, PhD, reviews emerging data on the challenging treatment of non-clear cell renal cell carcinoma.

COSMIC-313: Frontline Triplet Therapy in Advanced RCC

January 16th 2023

Experts discuss data from the COSMIC-313 study investigating a triplet combination therapy for the frontline treatment of advanced renal cell carcinoma.

Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial

January 9th 2023

Dr Moshe Orenstein reviews the 5-year data update of the CheckMate 214 trial in favorable risk subgroups of advanced renal cell carcinoma.

Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment

January 9th 2023

Drs Hammers and Orenstein describe how they manage the side effects of IO/IO combination treatments in their patients with advanced renal cell carcinoma.

Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment

December 22nd 2022

Hans Hammers, MD, PhD, details his strategies for dosing lenvatinib in patients with advanced renal cell carcinoma.

Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

December 22nd 2022

Drs Hans Hammers reviews updated efficacy data on the use of lenvatinib plus pembrolizumab for frontline advanced renal cell carcinoma treatment.

Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC

December 15th 2022

Moshe Ornstein, MD, MA, explains his reasoning for starting patients with advanced renal cell carcinoma on an IO/IO combination regimen.

Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

December 15th 2022

Hans Hammers, MD, PhD, describes how patients with advanced renal cell carcinoma are risk-stratified, and the go-to treatment approach for intermediate risk patients.

Dr. Ornstein on Toxicity Concerns for Neoadjuvant Therapy in Localized RCC

September 9th 2022

Moshe Ornstein, MD, MA, discusses toxicity concerns when treating renal cell carcinoma.

NEXT PAGE
PREVIOUS PAGE